Edison Investment Research Limited: Medlab Clinical (MDC): Initiation - Novel drug delivery and cannabinoids against pain
Medlab's lead product is NanaBis, a combination of THC and CBD (1:1) cannabinoids encapsulated in NanoCelle particles, which enable a convenient buccal spray formulation.
- Medlab's lead product is NanaBis, a combination of THC and CBD (1:1) cannabinoids encapsulated in NanoCelle particles, which enable a convenient buccal spray formulation.
- Once the product reformulation is completed (guidance is eight to 10 months), NanaBis will re-enter clinical development (potentially Phase III) as a fully synthetic, non-opioid pain relief drug optimised with proprietary delivery technology aimed at a vast market.
- About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors.
- Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector.